{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Definition of Treatment Response\n\n* The primary outcome in Cushing's disease will the % responders, a responder is defined as a patient with 2 consecutive 24h urinary free cortisols within the normal reference range in association with no clinical signs of disease progression.\n* Secondary outcomes will include the % reduction in 24h UFC (derived by comparison of the mean of 2 baseline 24h UFC values with mean of the two lowest consecutive 24h UFC values while on study treatment in association with no clinical signs of disease progression).","groups":[{"description":"Rosiglitazone maleate :","id":"OG000","title":"Rosiglitazone"}],"paramType":"NUMBER","populationDescription":"Sample size was too small to do a valid analysis.","reportingStatus":"POSTED","timeFrame":"7 weeks","title":"Number of Responders","type":"PRIMARY","unitOfMeasure":"participants"}